Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SABRATEK TAILORING SEAMLESS MULTI-THERAPY INFUSION SYSTEM SALES GROWTH STRATEGY TO ALTERNATE-SITE MARKET; COMPANY EXPECTS TO NET $27.1 MIL. IN PUBLIC OFFERING

This article was originally published in The Gray Sheet

Executive Summary

Sabratek Corporation is hoping that its products to facilitate the treatment of patients in alternate-site settings will deliver a seamless revenue stream for the firm. To address the need for "cost-effective movement of patients along the continuum of alternate-site care," the company has developed the Seamless Delivery System of "software based infusion devices and related interactive information system," the firm says in a preliminary prospectus for an initial public offering.

You may also be interested in...



'Purple Drank' Drug Cocktail Linked To France's Latest Reverse-Switch

Promethazine has been reverse-switched from OTC to prescription status in France, with rising abuse of the drug in the so-called Purple Drank cocktail one of the motivating factors for the move by the country's health ministry.

P&G Causes Friction With UK Cosmetics Firm Over Ad Claim

Can shaving ever be “friction free”? Not according to Procter & Gamble, which challenged in a complaint to the UK Advertising Standards Authority a claim made by a British cosmetics firm FFS that it provided a “friction free” shaving experience for women via its subscription razor service.

UK Readies Medtech And Pharma Sectors For Regulatory Life Outside The EU

Work has started on UK-only regulations for the medtech and medicines sectors, to ensure that the regulatory framework not only functions but can also react swiftly to needs after the UK leaves the EU. This article is part two of two.

UsernamePublicRestriction

Register

MT005982

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel